Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have prostate cancer that no longer responds to androgen ablation therapy.

Key facts

Study ID

NCT00060437

Run by

National Cancer Institute (NCI)

Starts

2003-10-01

Expected to finish

2004-04-01

Last updated by the study team

2013-06-19

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.